MiR-99b-5p suppressed proliferation of human osteoblasts by targeting FGFR3 in osteoporosis
- PMID: 34156640
- DOI: 10.1007/s13577-021-00567-3
MiR-99b-5p suppressed proliferation of human osteoblasts by targeting FGFR3 in osteoporosis
Abstract
Osteoporosis is a common skeletal disease characterized by reduced bone mass partially caused by an imbalance between bone resorption and formation. Considering the potential role of microRNAs (miRNAs) in osteoporosis, we attempted to identify deregulated miRNA that participates in the pathogenesis of osteoporosis. We analyzed online datasets for differentially expressed miRNAs and predicted deregulated miRNA target genes, applied these genes for signaling pathway enrichment annotation, and selected the possible miR-99b-5p/FGFR3 axis. Within osteoporosis bone tissues, miR-99b-5p was upregulated and FGFR3 was downregulated. miR-99b-5p overexpression inhibited osteoblast proliferation and osteogenesis-related genes expression, whereas FGFR3 overexpression exerted opposite effects upon the proliferation of osteoblasts and osteogenesis-related genes expression. By direct targeting, miR-99b-5p inhibited FGFR3 expression. Moreover, FGFR3 silencing significantly reversed the roles of miR-99b-5p inhibition in the proliferation of osteoblasts and osteogenesis-related genes expression. In conclusion, we identify a deregulated miRNA/mRNA axis in osteoporosis and osteogenic differentiation, namely the miR-99b-5p/FGFR3 axis; through targeting FGFR3, miR-99b-5p inhibits osteoblast proliferation and activity, which might subsequently affect the bone formation in osteoporosis progression.
Keywords: FGFR3; Osteoblast; Osteoporosis; The Ras signaling; miR-99b-5p.
© 2021. Japan Human Cell Society.
Similar articles
-
Exosomal miR-99b-5p Secreted from Mesenchymal Stem Cells Can Retard the Progression of Colorectal Cancer by Targeting FGFR3.Stem Cell Rev Rep. 2023 Nov;19(8):2901-2917. doi: 10.1007/s12015-023-10606-1. Epub 2023 Aug 31. Stem Cell Rev Rep. 2023. PMID: 37653181
-
MiR-100-5p inhibits osteogenic differentiation of human bone mesenchymal stromal cells by targeting TMEM135.Hum Cell. 2022 Nov;35(6):1671-1683. doi: 10.1007/s13577-022-00764-8. Epub 2022 Aug 10. Hum Cell. 2022. PMID: 35947339
-
miR-1249-5p regulates the osteogenic differentiation of ADSCs by targeting PDX1.J Orthop Surg Res. 2021 Jan 6;16(1):10. doi: 10.1186/s13018-020-02147-x. J Orthop Surg Res. 2021. PMID: 33407691 Free PMC article.
-
MicroRNA functions in osteogenesis and dysfunctions in osteoporosis.Curr Osteoporos Rep. 2013 Jun;11(2):72-82. doi: 10.1007/s11914-013-0143-6. Curr Osteoporos Rep. 2013. PMID: 23605904 Free PMC article. Review.
-
Focusing on OB-OC-MΦ Axis and miR-23a to Explore the Pathogenesis and Treatment Strategy of Osteoporosis.Front Endocrinol (Lausanne). 2022 Jul 14;13:891313. doi: 10.3389/fendo.2022.891313. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35909545 Free PMC article. Review.
Cited by
-
Human bone marrow mesenchymal stem cells-derived exosomes attenuated prostate cancer progression via the miR-99b-5p/IGF1R axis.Bioengineered. 2022 Feb;13(2):2004-2016. doi: 10.1080/21655979.2021.2009416. Bioengineered. 2022. PMID: 35030978 Free PMC article.
-
T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: correlation with QCT-derived bone mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal women.Quant Imaging Med Surg. 2023 Jul 1;13(7):4130-4146. doi: 10.21037/qims-22-1247. Epub 2023 May 31. Quant Imaging Med Surg. 2023. PMID: 37456293 Free PMC article.
-
The MicroRNAs in the Pathophysiology of Osteoporosis.Int J Mol Sci. 2024 Jun 5;25(11):6240. doi: 10.3390/ijms25116240. Int J Mol Sci. 2024. PMID: 38892426 Free PMC article. Review.
-
Mesenchymal stromal/stem cell-derived exosomes and genitourinary cancers: A mini review.Front Cell Dev Biol. 2023 Jan 4;10:1115786. doi: 10.3389/fcell.2022.1115786. eCollection 2022. Front Cell Dev Biol. 2023. PMID: 36684446 Free PMC article. Review.
-
Regulatory mechanisms of autophagy-related ncRNAs in bone metabolic diseases.Front Pharmacol. 2023 Dec 7;14:1178310. doi: 10.3389/fphar.2023.1178310. eCollection 2023. Front Pharmacol. 2023. PMID: 38146458 Free PMC article. Review.
References
-
- Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841–50. - DOI
-
- Seeman E. Estrogen, androgen, and the pathogenesis of bone fragility in women and men. Curr Osteoporos Rep. 2004;2:90–6. - DOI
-
- Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin N Am. 2005;34:1015–30, xi. - DOI
-
- Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2011;13:27–38. - DOI
-
- Bianco P, Sacchetti B, Riminucci M. Stem cells in skeletal physiology and endocrine diseases of bone. Endocr Dev. 2011;21:91–101. - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical